Triple Negative Breast Cancer (TNBC) Treatment Market Will Grow at Highest Pace owing to Rising R&D Investments
Triple negative breast cancer (TNBC) therapeutics refer to drugs that are used for the treatment of triple negative breast cancer. Triple negative breast cancer is an aggressive type of breast cancer wherein the cancer cells do not have estrogen receptors, progesterone receptors, and excess HER2 proteins. These cancer cells grow and spread faster as compared to other breast cancer types. Triple negative breast cancer therapeutics aim to inhibit cancer cell growth and destroy cancerous cells. The key drugs used in the treatment of TNBC include cisplatin, carboplatin, docetaxel, paclitaxel, epirubicin, doxorubicin, 5-fluorouracil, capecitabine, gemcitabine, and nab-paclitaxel. The need for targeted and effective TNBC therapeutics are rising owing to the lack of effective treatment options and rising incidence rates of this type of breast cancer.
The triple negative breast cancer (TNBC) treatment market is estimated to be valued at USD 1000 million in 2024 and is expected to reach USD 1432 million by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.
Key Takeaways
Key players operating in the triple negative breast cancer therapeutics market are F. Hoffmann-La Roche Ltd, AstraZeneca, Merck & Co., Inc., Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., and Genentech, Inc.
Rising awareness regarding early detection and treatment of breast cancer is fueling the demand for effective therapeutics. According to the World Cancer Research Fund International, around 2 million new cases of breast cancer are diagnosed worldwide each year.
Advances in cancer biology and immunology are facilitating the development of novel targeted therapeutics and personalized medicines for TNBC. Ongoing clinical trials are evaluating the safety and efficacy of immunotherapy drugs, PARP inhibitors, and epigenetic modifiers for Triple Negative Breast Cancer (TNBC) Treatment Market.
Market Trends
Growing popularity of biosimilars: Several companies are focusing on developing biosimilar versions of patented TNBC drugs to provide more affordable treatment options. This is expected to reduce the treatment costs.
Personalized medicine approach: Growing understanding of molecular heterogeneity of TNBC is facilitating the development of biomarkers for patient stratification and targeted therapeutics. A personalized medicine approach could improve treatment outcomes.
Market Opportunities
Immunotherapy drugs: Ongoing research toward understanding tumor microenvironment is fueling the development of immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer for TNBC immunotherapy.
Novel drug targets: Emerging insights into genetic alterations and deregulated signaling pathways in TNBC provide opportunities for developing drugs targeting VEGF, mTOR, FGFR, etc. Several targeted therapies are under clinical trials.
Impact of COVID-19 on Triple Negative Breast Cancer (TNBC) market growth
The COVID-19 pandemic has significantly impacted the TNBC market. During the initial lockdown phase, screening programs and elective surgeries were postponed globally to avoid overburdening the healthcare systems and prioritize resources to deal with the pandemic. This led to a decline in the number of new cases being diagnosed. However, the treatment for those already diagnosed continued. With the resumption of screening programs post lockdowns, the number of new cases has seen an uptick. But managing the treatment of these new cases along with existing patients has become challenging given the resource constraints faced by most healthcare systems due to the pandemic. Teleoncology has helped to some extent in continuing care and monitoring of patients through virtual consultations. However, access to essential diagnostic tests and specialized surgeries remains limited in certain regions. The economic downturn resulting from the pandemic has also made treatment unaffordable for some patients. Drugmakers have tried to assist through patient support programs. Vaccination drives are expected to help free up more resources to focus on cancer care. Also, development of new targeted therapies and immunotherapies continues which will support future growth once the crisis starts subsiding.
Geographical concentration of TNBC market
In terms of value, the North American region accounts for the major share of the global TNBC market currently. This is mainly attributed to factors such as high incidence rates of breast cancer, developed healthcare infrastructure and greater access to advanced treatment options in the United States. Within the U.S., states like California, Texas and New York have a higher prevalence and consequently higher market value. The European region is the second largest market led by countries like Germany, France and the United Kingdom. However, the Asian market is witnessing fast growth led by China, Japan and India where growing awareness and increasing healthcare spending are supporting demand.
Fastest growing region in TNBC market
The Asia Pacific region is poised to be the fastest growing market for TNBC globally during the forecast period. This is particularly due to the improving accessibility ofadvanced diagnostics and targeted drugs in large populous nations like China and India where the burden of breast cancer is rising significantly. Initiatives by governments as well as private organizations are helping create awareness about early detection and management of breast cancer. In addition, healthcare infrastructure is expanding in rural and remote areas as well. All these factors along with continued economic development are expected to drive strong growth in the TNBC market across Asia Pacific in the coming years.
Get More Insights On- Triple Negative Breast Cancer (TNBC) Treatment Market
Get This Report in Japanese Language: トリプルネガティブ乳がん（TNBC）治療市場
Get This Report in Korean Language: 삼중 음성 유방암(TNBC) 치료 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
Comments
0 comment